NANETS Webinar Series:Peptide Receptor Radionuclide Therapy (PRRT): Background, Published Results, Patient Selection Details, Sequencing of Therapy, Future Directions

NANETS Webinar Series:
Peptide Receptor Radionuclide Therapy (PRRT): Background, Published Results, Patient Selection Details, Sequencing of Therapy, Future Directions

July 23, 2020, 6:00 pm - 7:00 pm ET

Presenters:
Jonathan Strosberg, MD, Moffitt Cancer Center
Lisa Bodei, MD, Memorial Sloan Kettering Cancer Center

Learning Objectives:

• Understand the regulatory considerations for the administration of 177Lu-DOTATATE
• Appreciate the logistical considerations and space planning for treatment
• Understand the adjunctive medication options and their appropriate utilization
• Understand where 177Lutetium-dotatate might fit within the neuroendocrine tumor treatment landscape
• Understand impact of PRRT on key endpoints including progression-free survival and health-related quality of life
• Identify potential risks of 177Lutetium-dotatate, including long-term myelotoxicity

The CMEsolutions designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™, MOC and nursing continued education credits